Retatrutide is a potent, multi-targeting peptide under investigation for research applications. It selectively engages multiple receptors, including GLP-1, GIP, and GPR121, with potential for laboratory-based studies. This compound is intended exclusively for research use only.
Price range: $80.00 through $275.00
Every serious peptide company prominently displays this. Example Research Use Only All products offered by Dakota Peptology are intended strictly for laboratory research purposes.
Every serious peptide company prominently displays this. Example Research Use Only All products offered by TruPeptides are intended strictly for laboratory research purposes.
Retatrutide is a novel peptide-based research compound under investigation in preclinical and early-stage clinical studies for its potential metabolic and therapeutic effects. This compound is being explored in research settings for its potential impact on conditions associated with energy metabolism, insulin sensitivity, and body composition. Below is a detailed overview of its research context and key scientific focus areas.
Retatrutide is a multifunctional peptide derived from the natural human peptide GLP-1/GLP-2/GIP receptor agonist, targeting a broader spectrum of metabolic pathways compared to traditional single-receptor agonists. Its development is driven by the growing body of evidence linking receptor co-activation to enhanced therapeutic efficacy in the management of conditions such as obesity, type 2 diabetes, and metabolic dysfunction. Research involving this compound is primarily conducted in controlled laboratory, animal, and early-phase human studies to evaluate its mechanisms of action, safety profile, and potential therapeutic applications.
Retatrutide has been investigated in preclinical models for its potential to improve insulin sensitivity, reduce body weight, and modulate gastrointestinal functions. The dual targeting of GLP-1/GLP-2 and GIP receptors is hypothesized to enhance satiety, regulate glucose metabolism, and support tissue repair in metabolic disorders. Studies have explored its effects on pancreatic beta-cell function, lipid metabolism, and inflammatory pathways, with particular emphasis on its ability to restore metabolic homeostasis. Early findings suggest promising effects on body composition, including reductions in visceral fat accumulation, though further research is required to fully elucidate its long-term safety and efficacy.
This compound is intended solely for research use in accredited academic, pharmaceutical, or biotech institutions. It must be handled with the utmost care in accordance with institutional biosafety protocols. Retatrutide is not approved for human or animal therapeutic, diagnostic, or cosmetic purposes. Unauthorized distribution, possession, or use is strictly prohibited by law and may constitute a violation of regulatory requirements. For research use only. Not for human or animal consumption.
Retatrutide is a novel synthetic peptide designed as a triple agonist targeting glucagon, GLP-1 (glucagon-like peptide-1), and GIP (glucose-dependent insulinotropic polypeptide) receptors.
This multi-receptor approach is intended to enhance metabolic regulation by combining appetite suppression, energy expenditure, and glucose control within a single compound.
The objective of this clinical research was to evaluate the safety, tolerability, and efficacy of retatrutide in reducing body weight and improving metabolic markers in adults with obesity or overweight.
Investigators also examined its effects on cardiovascular risk factors and overall metabolic health.
In a phase 2 randomized, double-blind, placebo-controlled trial, participants received once-weekly subcutaneous injections of retatrutide at varying dose levels.
The study evaluated outcomes over a 48-week period, including changes in body weight, waist circumference, glycemic markers, and lipid profiles.
Retatrutide demonstrated substantial reductions in body weight across multiple dose groups, with higher doses producing greater effects.
Participants also showed decreases in waist circumference and improvements in overall body composition, indicating a reduction in adipose tissue.
Treatment with retatrutide was associated with improvements in blood glucose control, lipid markers, and blood pressure.
These changes suggest a broad metabolic impact, extending beyond weight reduction to include cardiovascular risk factor modulation.
Retatrutide activates GLP-1 and GIP receptors to enhance insulin secretion and reduce appetite, while glucagon receptor activation contributes to increased energy expenditure.
This triple agonist mechanism creates a synergistic effect on energy balance, combining reduced caloric intake with increased metabolic activity.
Retatrutide represents a next-generation approach in peptide-based metabolic research, expanding beyond dual agonists to include triple hormonal targeting.
Ongoing studies are exploring its long-term effects and potential applications in obesity, type 2 diabetes, and related metabolic disorders.
Retatrutide has demonstrated significant reductions in body weight and improvements in metabolic parameters in controlled clinical studies.
Its triple receptor agonist activity distinguishes it as a promising candidate in ongoing metabolic and obesity research.
